Valuation: Savara Inc.

Market Cap 1.21B 1.1B 1.01B 913M 1.72B 113B 1.79B 12.19B 4.82B 60.83B 4.53B 4.43B 192B P/E 2026 *
-7.41x
P/E 2027 * -11.4x
Enterprise Value 733M 666M 615M 555M 1.05B 68.5B 1.09B 7.41B 2.93B 36.96B 2.75B 2.69B 117B EV / Sales 2026 *
545x
EV / Sales 2027 * 10.9x
Free-Float
97.31%
Yield 2026 *
-
Yield 2027 * -
1 day+6.58%
1 week-4.11%
Current month-0.73%
1 month+3.35%
3 months-10.89%
6 months-2.55%
Current year-20.65%
1 week 4.35
Extreme 4.35
5.03
1 month 4.13
Extreme 4.13
5.2
Current year 4.13
Extreme 4.13
6.49
1 year 4.13
Extreme 4.13
7
3 years 1.89
Extreme 1.89
7
5 years 1.02
Extreme 1.02
7
10 years 0.69
Extreme 0.69
17.19
Manager TitleAgeSince
Chief Executive Officer 55 30/11/2020
Director of Finance/CFO 57 14/07/2026
Chief Tech/Sci/R&D Officer - 29/02/2024
Director TitleAgeSince
Director/Board Member 58 31/01/2009
Director/Board Member 77 30/09/2010
Director/Board Member 73 30/09/2013
Date Insider Type Main position Quantity % Market Cap. Importance
24/09/26 Tax

Executive/Senior Manager

-29,323 0.0143%
15/07/26 Free

Chief Financial Officer

105,000 0.0512%
18/03/26 Exercice

Chief Financial Officer

850,254 0.4179%
Change 5-day change 1-year change 3-year change Capi.($)
+6.58%-4.11%+14.75%+27.60% 1.21B
-1.34%-4.12%+53.70%+68.83% 66.37B
+0.59%-1.83%+8.98%+90.68% 58.86B
+0.45%+0.48%+26.00%+86.67% 55.22B
-2.33%-4.03%+10.75%+114.52% 47.21B
-0.46%-7.16%+17.30%+24.15% 42.45B
-2.58%+2.22%+14.73%+41.28% 36.44B
-1.50%-11.84%+125.70%+633.09% 35.19B
-0.17%-1.83%+82.46%+57.48% 32.66B
-1.35%-0.99%-40.70%+385.60% 26.73B
Average -0.23%-3.84%+31.37%+152.99% 40B
Weighted average by Cap. -0.87%-2.95%+33.19%+141.98%

Financials

2026 *2027 *
Net sales 1.34M 1.22M 1.13M 1.02M 1.92M 126M 1.99M 13.59M 5.37M 67.79M 5.04M 4.94M 214M 78.5M 71.26M 65.83M 59.39M 112M 7.33B 116M 793M 314M 3.96B 295M 288M 12.5B
Net income -151M -137M -127M -114M -216M -14.14B -224M -1.53B -605M -7.63B -568M -556M -24.1B -97.06M -88.11M -81.39M -73.43M -139M -9.07B -144M -981M -388M -4.89B -364M -356M -15.46B
Net Debt -473M -430M -397M -358M -676M -44.22B -702M -4.78B -1.89B -23.86B -1.78B -1.74B -75.39B -352M -319M -295M -266M -502M -32.86B -522M -3.55B -1.41B -17.73B -1.32B -1.29B -56.03B
Projected Income Statement - Annual - Savara Inc.
Logo Savara Inc.
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company's lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Employees
70
Date Price Change Volume
18/11/26 US$4.795 +7.03% 1,977,134
17/11/26 US$4.480 +0.34% 3,844,092
16/11/26 US$4.465 -3.77% 2,797,753
13/11/26 US$4.640 -1.69% 3,231,792
12/11/26 US$4.720 -5.41% 4,297,079
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Savara Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.480USD
Average target price
11.06USD
Spread / Average Target
+146.78%
  1. Stock Market
  2. Stocks
  3. SVRA Stock